Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance

May 04, 2015

HAYWARD, Calif., May 4, 2015 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) announced that it has filled two key executive leadership roles, appointing  Donna M. Hughes, as Senior Vice President, Human Resources and Deborah M. Penza, as Senior Vice President, Chief Compliance Officer. Both Ms. Hughes and Ms. Penza will report to Impax's President and Chief Executive Officer, Fred Wilkinson.

"We are excited that Donna and Deborah have joined the Impax team," said Fred Wilkinson, President and Chief Executive Officer of Impax. "They bring a proven track record of developing and implementing policies and procedures that will benefit our Company and our employees. The addition of these highly accomplished and experienced executives further strengthens our leadership team as we continue to position the Company to execute on our strategic initiatives."  

Ms. Hughes, who has over 20 years of legal and human resources experience, will oversee all of Impax's human resource functions. She joins Impax from Actavis, where she was Vice President, Labor and Employment, and a member of Actavis' Global Leadership Team and Human Resources Leadership Team. Ms. Hughes was responsible for the management of all labor and employment law matters company-wide, including employment litigation, benefits, immigration, acquisition due diligence, post-merger integration, and global human resources issues. Prior to joining Actavis, Ms. Hughes served as Director and Assistant General Counsel for Circuit City Stores, Inc., where she managed the company's employment law department. She spent seven years in private practice and worked at New Jersey law firms Pitney, Hardin, LLP and St. John & Wayne, LLC. She has previously served as adjunct faculty for Rutgers University School of Management, Rutgers University's Political Science Department, and Seton Hall University School of Law. Ms. Hughes received her Juris Doctorate from Rutgers University School of Law-Newark and her Bachelor of Arts from Rutgers College, Rutgers University.

Ms. Penza has over 20 years of experience as both a consultant and a compliance professional implementing and operating compliance programs in the healthcare industry. She will be responsible for the development, implementation and oversight of Impax's corporate compliance program. Ms. Penza joins Impax from Actavis, where she was Chief Compliance Officer. Prior to joining Actavis, Ms. Penza served as the Vice President, Corporate Compliance for Elan Corporation, plc, where she led the company's global ethics and compliance program. Before joining Elan, she was a Vice President of Strategic Management Systems, Inc., where she developed and implemented compliance programs for healthcare clients and provided guidance on compliance program management. Ms. Penza received her Juris Doctorate from the George Mason University School of Law, and she possesses a Master of Arts from The George Washington University. She received her Bachelor of Arts from Florida Atlantic University.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at:

Company Contact:            
Mark Donohue
Investor Relations and Corporate Communications 
(215) 558-4526                                                                                


To view the original version on PR Newswire, visit:

SOURCE Impax Laboratories, Inc.